|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
This short review gives an overview on the main contradicting findings on the role of 11β-HSD1 in the development of visceral obesity and diabetes type 2.
|
30796905 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
11β HSD 1 activity is higher in type 2 diabetes mellitus subjects, especially those who are lean.
|
30678666 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
The inhibition of 11β-HSD1 has been shown to attenuate the development of type 2 diabetes mellitus, insulin resistance, metabolic syndrome and other diseases mediated by excessive cortisol production.
|
31664610 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
These results suggest that the 11β-HSD1 inhibitor, INU-101 may serve as a novel drug candidate for the treatment of type 2 diabetes and metabolic syndrome.
|
30096297 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
11β-HSD1 has been recognized as a potential therapeutic target for type 2 diabetes.
|
29221204 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
Thus, 11β-HSD1 is a promising target for the treatment and prevention of type 2 diabetes mellitus with obesity.
|
29078846 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
H6PDH and 11β-HSD1 might be the effective and prospective targets for T2DM and metabolic syndromes, based on the interplay between these two enzymes.
|
28751144 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The association analysis indicated that HSD11B1 rs12086634 TG contributed to an increased risk of both T2D (OR=1.91; 95% CI-1.33-2.76, P=0.0005) and metS (OR=2.37; 95% CI-1.39-4.05, P=0.0015), but HSD11B1 rs846910 AG contributed to an increased risk of T2D (OR=1.62; 95% CI-1.02-2.57, P=0.03) only.
|
28750217 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
Together, our data suggest that GRb1 may increase insulin sensitivity through suppressing 11β-HSD1 in treatment of T2D.
|
28386332 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
We consider the potential of inhibition of 11βHSD1 as a therapeutic strategy that might address multiple complications in patients with type 2 diabetes, and provide our thoughts on future directions in this field.
|
24710966 |
2014 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Impact of HDL genetic risk scores on coronary artery calcified plaque and mortality in individuals with type 2 diabetes from the Diabetes Heart Study.
|
23799899 |
2013 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Regeneration of cortisol by 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) within liver and adipose tissue may be of pathophysiological importance in obesity and the metabolic syndrome. single nucleotide polymorphisms (SNPs) in HSD11B1, the gene encoding 11β-HSD1, have been associated with type 2 diabetes and hypertension in population-based cohort studies, and with hyperandrogenism in patients with the polycystic ovary syndrome (PCOS).
|
21622477 |
2011 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
The selective inhibitors of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) have considerable potential for treating type 2 diabetes mellitus and metabolic syndrome.
|
21315688 |
2011 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, HSD11B1 and H6PD polymorphisms may not be associated with type 2 diabetes and metabolic syndrome.
|
21869537 |
2011 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Polymorphisms in HSD11B1, the gene encoding 11β-hydroxysteroid dehydrogenase type 1 enzyme, have been associated with obesity, metabolic syndrome, and type 2 diabetes.
|
21117953 |
2011 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
Polymorphisms in 11-β hydroxysteroid dehydrogenase type 1 (11β-HSD1, encoded by HSD11B1) have been reported to be associated with obesity-related cardiovascular risk factors, such as type II diabetes and hypertension.
|
21402901 |
2011 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Polymorphisms in HSD11B1, the gene encoding 11 beta-HSD1, have been associated with metabolic phenotype in humans, including type 2 diabetes and hypertension.
|
19934376 |
2010 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The variations in HSD11B1 were not associated with susceptibility to type 2 diabetes or metabolic phenotypes in Koreans.
|
19571556 |
2009 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Failure to down-regulate HSD11B1 activity in patients with type 2 diabetes may contribute to the pathogenesis of T2DM.
|
18963204 |
2008 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
RGD |
Increased expression and activity of 11beta-HSD-1 in diabetic islets and prevention with troglitazone.
|
14697232 |
2004 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
We confirmed that adipocyte 11beta-HSD1 mRNA concentrations were associated with adiposity, and showed that genetic variations in the HSD11B1 gene were associated with Type 2 diabetes mellitus, plasma insulin concentrations and insulin action, independent of obesity.
|
15156315 |
2004 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
GeneticVariation
|
disease |
LHGDN |
We confirmed that adipocyte 11beta-HSD1 mRNA concentrations were associated with adiposity, and showed that genetic variations in the HSD11B1 gene were associated with Type 2 diabetes mellitus, plasma insulin concentrations and insulin action, independent of obesity.
|
15156315 |
2004 |